Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05331144 · ClinicalTrials.gov registry record · Phase 2
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
A Phase 2 study of Hypertension and Subjective Cognitive Decline, sponsored by Rong Zhang.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT05331144 is a Phase 2 study of Hypertension and Subjective Cognitive Decline that is actively recruiting participants, run by Rong Zhang. The registered enrollment target is 180 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05331144, a Phase 2 study of Hypertension and Subjective Cognitive Decline, is actively recruiting participants, sponsored by Rong Zhang.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.
Conditions Studied
Interventions
- DRUG Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)
- OTHER PCP
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05331144
The ClinicalTrials.gov registry entry for NCT05331144 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The listed sponsor is Rong Zhang, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) is the first listed.
NCT05331144 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05331144 about?
NCT05331144 is a clinical study titled "Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)". The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dem...
What is the current status of trial NCT05331144?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2022-10-25. Estimated completion is 2027-12-31.
What conditions does trial NCT05331144 study?
This clinical trial studies the following conditions: Hypertension, Subjective Cognitive Decline, Cognitively Normal Older Adults, Family History of Dementia.
What interventions are being tested in trial NCT05331144?
The interventions under investigation include: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) (DRUG), PCP (OTHER).
Who is sponsoring clinical trial NCT05331144?
This trial is sponsored by Rong Zhang, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05331144 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.